1. Hu S, Lu H, Xie W, Wang D, Shan Z, Xing X, Wang XM, Fang J, Dong W, Dai W, Guo J, Zhang Y, Wen S, Guo XY, Chen Q, Bai F, Wang Z. TDO2 + myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma. J Clin Invest. 2022;19:132.
2. Finck AV, Blanchard T, Roselle CP, Golinelli G, June C. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022;4:28.
3. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;8:17.
4. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;2:70.
5. Zhang Q, Shi D, Guo M, Zhao H, Zhao Y, Yang X. Radiofrequency-activated pyroptosis of Bi-valent Gold Nanocluster for Cancer Immunotherapy. ACS Nano. 2023;1:17.